Friday, 06 December 2024


BioIVT and Krishgen BioSystems partner to enhance clinical research in South Asia

08 November 2024 | News

To provide researchers in India, Bangladesh and Nepal with access to a wider range of innovative, biological materials

image credit- shutterstock

image credit- shutterstock

US-based BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, has announced an exclusive agreement with India headquartered Krishgen BioSystems, a leading provider of life science research tools and services for over two decades in India, Bangladesh and Nepal.

Krishgen’s long-standing experience and strong presence in the region, combined with BioIVT’s industry-leading products, will create unparalleled opportunities for researchers to access high-quality, reliable solutions.

Through this agreement, Keishgen BioSystems exclusively represents BioIVT’s comprehensive portfolio of biofluids, tissues, cell products, media, and subcellular fractions/enzymes in India, Bangladesh and Nepal.

This diverse range of biological materials is essential for research in areas such as drug discovery, development, toxicology and personalised medicine. The commercial relationship will not only provide faster lead times and competitive pricing but also ensure ongoing technical support and customer service, further enhancing the overall research experience.

Dimas Neto, Director, Global Channel Partnerships at BioIVT said, “Together, we remain dedicated to advancing scientific discoveries that have the potential to transform healthcare and improve patient outcomes worldwide.”

Krisha Jain, VP, International Business Development at Krishgen BioSystems said, “We believe that Krishgen BioSystems and BioIVT’s shared commitment to providing researchers with the highest quality biological materials has been a driving force behind our success.”

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account